Suppr超能文献

欧洲原发性肝癌、胰腺癌和胆管癌患者的生存率。欧洲癌症治愈评估研究组(EUROCARE)

Survival of patients with primary liver cancer, pancreatic cancer and biliary tract cancer in Europe. EUROCARE Working Group.

作者信息

Faivre J, Forman D, Estève J, Obradovic M, Sant M

机构信息

Côte d'Or Cancer Registry, University of Dijon, Faculté de Médecine, France.

出版信息

Eur J Cancer. 1998 Dec;34(14 Spec No):2184-90. doi: 10.1016/s0959-8049(98)00330-x.

Abstract

The EUROCARE Study is a European Union project to assemble survival data from population-based cancer registries and analyse them according to standard procedures. We investigated and compared liver, pancreatic and biliary tract cancer survival in 17 countries from 1985 to 1989. Time trends in survival over the 1978-1989 period were also investigated in 12 countries. The overall European mean 1 year relative survival was 16% for primary liver cancer, 26% for biliary tract cancer and 15% for pancreatic cancer. The corresponding 5-year relative survival was 5, 12 and 4%, respectively. Taking the European average as the reference, the relative risk (RR) of death was at least 20% higher for the three cancers in Denmark and Estonia. Survival tended to be higher in Spain for primary liver cancer and biliary tract cancer. Gender had little influence on survival whilst age at diagnosis was inversely related to prognosis. There was an improvement in 1-year relative survival rate for primary liver cancer: relative risk (RR) of 0.68 (95% confidence interval (CI) of 0.60-0.77) for 1987-1989 versus 1978-1980 and biliary tract cancer (RR 0.77, 95% CI 0.68-0.87). There was less variation in 5-year relative survival rate over time. Some intercountry survival differences for primary liver, biliary tract and pancreatic cancers exist over Europe. Differences in quality of care, in particular treatment aggressiveness, may explain some of these differences in survival. New approaches to the management of these cancers need to be found.

摘要

欧洲癌症患者治疗与生存研究(EUROCARE Study)是欧盟开展的一个项目,旨在收集基于人群的癌症登记处的生存数据,并按照标准程序进行分析。我们调查并比较了1985年至1989年期间17个国家的肝癌、胰腺癌和胆管癌患者的生存率。同时,我们还研究了1978年至1989年期间12个国家生存率随时间的变化趋势。欧洲原发性肝癌患者的总体1年相对生存率为16%,胆管癌为26%,胰腺癌为15%。相应的5年相对生存率分别为5%、12%和4%。以欧洲平均水平为参照,丹麦和爱沙尼亚这三种癌症的死亡相对风险(RR)至少高出20%。西班牙原发性肝癌和胆管癌患者的生存率往往更高。性别对生存率影响不大,而确诊时的年龄与预后呈负相关。原发性肝癌的1年相对生存率有所提高:1987年至1989年相对于1978年至1980年的相对风险(RR)为0.68(95%置信区间(CI)为0.60 - 0.77),胆管癌的相对风险(RR)为0.77(95%置信区间为0.68 - 0.87)。5年相对生存率随时间的变化较小。欧洲各国在原发性肝癌以及胆管癌和胰腺癌的生存率方面存在差异。医疗质量的差异,尤其是治疗的积极程度,可能是造成这些生存差异的部分原因。需要找到针对这些癌症的新治疗方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验